SummaryChronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years with Imatinib until leukemia cells acquire drug resistance through BCR-ABL1 mutations and progress into fatal B lymphoid blast crisis (LBC). Despite its clinical significance, the mechanism of progression into LBC is unknown. Here, we show that LBC but not CML cells express the B cell-specific mutator enzyme AID. We demonstrate that AID expression in CML cells promotes overall genetic instability by hypermutation of tumor suppressor and DNA repair genes. Importantly, our data uncover a causative role of AID activity in the acquisition of BCR-ABL1 mutations leading to Imatinib resistance, thus providing a rationale for the rapid develop...
Acquired resistance through genetic mutations is a major obstacle in targeted cancer therapy, but th...
The constitutive tyrosine kinase activity of the BCR-ABL oncogene is central for the pathogenesis of...
The tyrosine kinase inhibitor imatinib is highly effective in the treatment of chronic myelogenous l...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
SummaryChronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many...
Background: BCR-ABL1-positive ALL is the most frequent and prognostically most unfavorable subtype o...
The Philadelphia chromosome (Ph) encodes the oncogenic BCR-ABL1 kinase and defines a subgroup of ALL...
Background: BCR-ABL1-positive ALL is the most frequent and prognostically unfavorable subtype of adu...
A characteristic feature of chronic myeloid leukaemia (CML) is the inevitable advancement from a tre...
Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) gene...
Very little is known about how acquired oncogenic mutations arise. In this issue of Cancer Cell, Kle...
The kinase activity of BCR-ABL1 is central to chronic myeloid leukaemia (CML) pathology. Clinical tr...
International audienceMost cancers become more dangerous by the outgrowth of malignant subclones wit...
AbstractThe fusion tyrosine kinase Bcr-Abl plays a fundamental role in the pathogenesis of chronic m...
Acquired resistance through genetic mutations is a major obstacle in targeted cancer therapy, but th...
The constitutive tyrosine kinase activity of the BCR-ABL oncogene is central for the pathogenesis of...
The tyrosine kinase inhibitor imatinib is highly effective in the treatment of chronic myelogenous l...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years ...
SummaryChronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many...
Background: BCR-ABL1-positive ALL is the most frequent and prognostically most unfavorable subtype o...
The Philadelphia chromosome (Ph) encodes the oncogenic BCR-ABL1 kinase and defines a subgroup of ALL...
Background: BCR-ABL1-positive ALL is the most frequent and prognostically unfavorable subtype of adu...
A characteristic feature of chronic myeloid leukaemia (CML) is the inevitable advancement from a tre...
Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) gene...
Very little is known about how acquired oncogenic mutations arise. In this issue of Cancer Cell, Kle...
The kinase activity of BCR-ABL1 is central to chronic myeloid leukaemia (CML) pathology. Clinical tr...
International audienceMost cancers become more dangerous by the outgrowth of malignant subclones wit...
AbstractThe fusion tyrosine kinase Bcr-Abl plays a fundamental role in the pathogenesis of chronic m...
Acquired resistance through genetic mutations is a major obstacle in targeted cancer therapy, but th...
The constitutive tyrosine kinase activity of the BCR-ABL oncogene is central for the pathogenesis of...
The tyrosine kinase inhibitor imatinib is highly effective in the treatment of chronic myelogenous l...